Sierra Oncology, Inc. Common Stock
SRRA
SRRA was delisted on the 30th of June, 2022.
109 hedge funds and large institutions have $1.06B invested in Sierra Oncology, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 71 funds opening new positions, 17 increasing their positions, 16 reducing their positions, and 36 closing their positions.
97% more first-time investments, than exits
New positions opened: 71 | Existing positions closed: 36
65% more capital invested
Capital invested by funds: $641M → $1.06B (+$417M)
45% more funds holding
Funds holding: 75 → 109 (+34)
6% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 16
13% less funds holding in top 10
Funds holding in top 10: 8 → 7 (-1)
38% less call options, than puts
Call options by funds: $8.79M | Put options by funds: $14.1M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VI
Versor Investments
New York
|
+$82.9M |
| 2 |
MF
Magnetar Financial
Evanston,
Illinois
|
+$58.1M |
| 3 |
TAL
TIG Advisors LLC
New York
|
+$46.8M |
| 4 |
BlackRock
New York
|
+$37.9M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
+$26.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
-$77.2M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$34.1M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$32M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$24.2M |
| 5 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$18.3M |
SRRA Hedge Fund Activity: Q2 2022 in Review
109 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Sierra Oncology, Inc. Common Stock (SRRA) for Q2 2022, worth a combined $1.06B — up 65% from $641M a quarter earlier.
Buyers outnumbered sellers: 71 funds opened new SRRA positions and 36 closed out — a net gain of 35 holders — while 17 added to existing stakes and 16 trimmed.
The largest buyer was Versor Investments, opening a new position worth an estimated $82.9M. The largest seller was Frazier Life Sciences Management, cutting an estimated $77.2M.
- 109 institutional investors held Sierra Oncology, Inc. Common Stock (SRRA) as of Q2 2022, up from 75 in Q1 2022.
- Funds reported $1.06B of Sierra Oncology, Inc. Common Stock stock for Q2 2022, up 65% quarter-over-quarter.
- 71 funds opened new Sierra Oncology, Inc. Common Stock positions in Q2 2022 and 36 closed out, a net change of +35 holders.
- The largest Sierra Oncology, Inc. Common Stock buyer in Q2 2022 was Versor Investments, an estimated $82.9M added.
- The largest Sierra Oncology, Inc. Common Stock seller in Q2 2022 was Frazier Life Sciences Management, an estimated $77.2M sold.
Based on aggregated 13F filings for Q2 2022.